Senescent Microglia Resolution via Maresins-Senolytics Combination
Quality Report Card click to collapse
From Analysis:
Neuroinflammation resolution mechanisms and pro-resolving mediators
SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation resolution. Are resolution failures druggable?
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Description
Mechanistic Overview
Senescent Microglia Resolution via Maresins-Senolytics Combination starts from the claim that modulating BCL2L1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Mechanistic Foundation Senescent microglia represent a distinct pathological cell state in Alzheimer's disease and aging that combines features of cellular senescence (growth arrest, senescence-associated secretory phenotype/SASP) with impaired microglial-specific functions (phagocytosis, surveillance, synaptic pruning). These "zombie" microglia accumulate in aged and diseased brains, constituting up to 30% of the microglial population in advanced Alzheimer's disease....
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Senescent Microglia
p16+ p21+ SA-beta-gal+
Growth arrested state"] --> B["SASP Secretion
IL-1alpha IL-6 IL-8
MMP-9 Complement factors"]
A --> C["Loss of Homeostatic
Functions
Impaired phagocytosis
Defective surveillance"]
D["Maresin 1 (MaR1)
Specialized Pro-resolving
Mediator"] --> E["LGR6 Receptor
Activation
G-protein coupled"]
E --> F["cAMP-CREB Signaling
Pathway Activation
Transcriptional reprogramming"]
F --> G["Anti-inflammatory
Gene Expression
IL-10 Arginase-1 FIZZ1"]
H["BCL2L1-Targeting
Senolytic Agent
ABT-263/Navitoclax"] --> I["BCL2L1 Inhibition
Anti-apoptotic protein
blockade"]
I --> J["Mitochondrial
Cytochrome C Release
Apoptosis initiation"]
A --> K["BCL2L1 Overexpression
Senescence survival
mechanism"]
K --> I
J --> L["Caspase 3/7 Activation
Apoptotic execution
pathway"]
L --> M["Selective Senescent
Microglia Elimination
Apoptotic clearance"]
G --> N["Enhanced Phagocytosis
Debris clearance
Amyloid-beta uptake"]
B --> O["Neuroinflammatory
Microenvironment
Synaptic damage"]
P["Combination Therapy
MaR1 + ABT-263
Dual mechanism"] --> D
P --> H
M --> Q["Microglial Population
Renewal
Healthy replacement cells"]
N --> R["Neuroprotective
Outcome
Restored brain homeostasis"]
Q --> R
S["Reduced SASP
Inflammatory resolution
Tissue repair"] --> R
G --> S
O -->|"blocks"| R
classDef normal fill:#4fc3f7,stroke:#2196f3
classDef therapeutic fill:#81c784,stroke:#4caf50
classDef pathology fill:#ef5350,stroke:#f44336
classDef outcome fill:#ffd54f,stroke:#ff9800
classDef molecular fill:#ce93d8,stroke:#9c27b0
class A,B,C,O pathology
class D,H,P therapeutic
class E,F,G,I,J,K,L,M,N,Q,S molecular
class R outcome
Dimension Scores
Legacy Card View — expandable citation cards
✓ Supporting Evidence 21
Foundational paper identifying senolytic drug targets
Validates ABT-263 as effective senolytic in vivo
Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenoca… MEDIUM▼
Demonstrates single-cell methods for identifying senescent populations
Identifies senescent microglial population in human AD using scRNA-seq
Mechanism of maresin pro-resolution effects on microglia
Preclinical efficacy in Alzheimer's model
Validates combination strategy over single agents
Human biomarker validation and prognostic value
BACKGROUND: The role of senescence in disease contexts is complex, however there is considerable evidence that depletion of senescent cells improves outcomes in a variety of contexts particularly related to aging, cognition, and neurodegeneration. Much research has shown previously that inflammation can promote cellular senescence. Microglia are a central nervous system innate immune cell that undergo senescence with aging and during neurodegeneration. The contribution of senescent microglia to multiple sclerosis, an inflammatory neurodegenerative disease, is not clear, but microglia are strongly implicated in chronic active lesion pathology, tissue injury, and disease progression. Drugs that could specifically eliminate dysregulated microglia in multiple sclerosis are therefore of great interest to the field. RESULTS: A single-cell analysis of brain tissue from mice subjected to experimental autoimmune encephalomyelitis (EAE), a mouse model of CNS inflammation that models aspects of multiple sclerosis (MS), identified microglia with a strong transcriptional signature of senescence including the presence of BCL2-family gene transcripts. Microglia expressing Bcl2l1 had higher expression of pro-inflammatory and senescence associated genes than their Bcl2l1 negative counterparts in EAE, suggesting they may exacerbate inflammation. Notably, in human single-nucleus sequencing from MS, BCL2L1 positive microglia were enriched in lesions with active inflammatory pathology, and likewi
A powerful way to discover key genes with causal roles in oncogenesis is to identify genomic regions that undergo frequent alteration in human cancers. Here we present high-resolution analyses of somatic copy-number alterations (SCNAs) from 3,131 cancer specimens, belonging largely to 26 histological types. We identify 158 regions of focal SCNA that are altered at significant frequency across several cancer types, of which 122 cannot be explained by the presence of a known cancer target gene located within these regions. Several gene families are enriched among these regions of focal SCNA, including the BCL2 family of apoptosis regulators and the NF-kappaBeta pathway. We show that cancer cells containing amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival. Finally, we demonstrate that a large majority of SCNAs identified in individual cancer types are present in several cancer types.
Comprehensive assessment of the genomic stability of human induced pluripotent stem cells for clinical applica… MEDIUM▼
BACKGROUND: Human induced pluripotent stem cells (hiPSCs) may acquire genomic alterations during reprogramming and culture, which poses significant risks for clinical applications. Current detection methods, such as karyotyping analysis, often fail to identify critical submicroscopic variations. This highlights an urgent need for comprehensive genomic surveillance strategies. METHODS: Three human iPSC lines were continually cultured in vitro for 50 passages, with genome alterations evaluated every 10 passages. The evaluation methods included karyotyping to detect chromosomal abnormalities, optical genome mapping (OGM) to identify copy number variations (CNVs) and structural variants (SVs), whole-exome sequencing (WES) to detect coding mutations, and RNA sequencing (RNA-seq) to detect the changes of gene expression. RESULTS: We detected accumulating chromosomal abnormalities (e.g., trisomy 12), SVs, CNVs, and sequence mutations in three hiPSC lines during extended culture. OGM effectively identified SVs and CNVs below karyotyping resolution, particularly recurrent genome abnormalities such as gains on chr17q, chr12p and chr20q. WES revealed coding mutations, including germline short variants and newly acquired somatic mutations, some of which were associated with tumors or diseases, such as CDH1, BCOR. Transcriptional changes correlated with genomic alterations, including dysregulation of oncogenes such as BCL2L1, KRAS and MDM2. Results demonstrate that each method had unique
Exploring the key molecular mechanisms and immune microenvironment of oxidative stress-related pathways in pan… MEDIUM▼
BACKGROUND: Pancreatic neuroendocrine tumor (pNET) is a heterogeneous tumor originating from pancreatic endocrine cells. Emerging evidence suggests that oxidative stress plays a crucial role in pNET pathogenesis, yet the precise molecular mechanisms and their interplay with the tumor microenvironment remain unclear. This study aims to systematically elucidate how oxidative stress-related pathways drive pNET progression through an integrated multi-omics approach. METHODS: We designed a three-tier analytical strategy to address interconnected scientific questions. First, to identify which oxidative stress-related genes are dysregulated in pNET, we performed differential expression analysis and weighted gene co-expression network analysis (WGCNA) on the GSE73338 dataset (63 pNET samples, 5 controls), intersecting the. results with oxidative stress gene sets to obtain 71 candidate genes. Second, to understand the functional implications of these genes, we conducted GO/KEGG enrichment analysis and constructed protein-protein interaction (PPI) networks, from which we identified BCL2L1 and PHGDH as key hub genes using three independent algorithms. We then assessed their diagnostic value through ROC analysis and built a prognostic nomogram model. Third, to explore how these key genes influence the tumor microenvironment, we performed immune infiltration analysis using CIBERSORTx. Fourth, to reveal upstream regulatory mechanisms, we constructed ceRNA networks and predicted transcripti
Characterization of the Direct and Indirect Inhibition of Apoptosis by Full-Length Recombinant Bcl-xL Monomers… MEDIUM▼
The Bcl-2 protein Bcl-xL is an inhibitor of intrinsic apoptosis which either directly inhibits the pore-forming Bcl-2 proteins, like Bax or Bak, or indirectly inhibits pore formation by sequestering the pro-apoptotic BH3-only activators. The structural basis of the inhibition of pore formation in the outer mitochondrial membrane is still largely unknown due to the lack of atomic resolution structures of the relevant inhibitory complexes at the membrane. Herein, a protocol to obtain high-yield recombinant monomeric full-length Bcl-xL proteins is presented. The monomeric Bcl-xL retains the ability to shuttle between membrane and aqueous environments and can successfully inhibit Bcl-2-induced membrane permeabilization via both modes of action, as proven by in vitro and in organelle assays with a minimal Bcl-2 interactome constituted by Bcl-xL, cBid, and Bax.
Navitoclax acts synergistically with irradiation to induce apoptosis in preclinical models of H3K27M-altered d… MEDIUM▼
Diffuse midline gliomas (DMGs) with histone H3K27M mutations represent a devastating paediatric brain cancer characterised by abysmal prognosis and limited treatment options. The only approved treatment is radiotherapy (RT), but most of the tumours relapse with fatal consequences. The effects of RT remain unknown because patients are not biopsied during treatment. Here, we sought to investigate whether irradiation leads to senescence induction in DMG and explore the efficacy of senolytics. We show that ionising radiation induces senescence in various H3K27M-altered DMG cell lines. Senescence induction is demonstrated by immunocytochemistry, RNA-sequencing and analysis of SASP factors by ELISA. Through testing several senolytic compounds, we identify that Bcl2 family inhibitors (e.g., Navitoclax) act as potent senolytics, driving senescent DMG cells into apoptosis, primarily via Bcl-xL inhibition. Reinforcing these findings, proteolysis-targeting chimeras (PROTACs) targeting Bcl-xL and galacto-conjugated Navitoclax (Nav-Gal) also exhibit strong senolytic activity against senescent DMG cancer cells. Finally, we show that a combination of irradiation with Navitoclax enhances cancer cell apoptosis in an orthotopic xenograft DMG model. Together, the data demonstrate that ionising irradiation leads to senescence induction in H3K27M-altered human DMG cell lines, making them particularly sensitive to apoptosis through Bcl-xL inhibition.
Senolytic elimination of therapy-induced senescent cells by ABT-263 improves chemotherapeutic efficacy in esop… MEDIUM▼
Esophageal squamous cell carcinoma (ESCC) is routinely treated with platinum-based chemotherapy but almost inevitably relapses. Our previous study demonstrated that cisplatin (CDDP) induced ESCC cell senescence, and senescent cells promoted the aggressive behaviors of neighboring cancer cells through the senescence-associated secretory phenotype (SASP). Notably, the use of 'senolytic' drugs that selectively remove senescent cells by inducing apoptosis has been proven to improve therapeutic efficacy, but their potential application in ESCC therapy has not yet been studied. In this study, we observed that therapy-induced ESCC cell senescence was associated with poor prognosis of ESCC patients. We found that anti-apoptotic BCL-2 family member BCL-XL mediated the survival of CDDP-induced senescent ESCC cells, and senolytic drug ABT-263 (navitoclax, an inhibitor of BCL-2 and BCL-XL) selectively eliminated senescent cells by triggering apoptosis, thereby attenuating SASP-driven ESCC cell proliferation and migration in vitro and improving CDDP efficacy in a mouse model of ESCC. Mechanistically, the enhanced interaction between BCL-XL and pro-apoptotic effector protein BAX conferred apoptosis resistance in senescent ESCC cells, and ABT-263 treatment disrupted this interaction to activate apoptosis. Overall, our data indicate that CDDP-induced senescent ESCC cells could be eliminated using senolytic drugs that target BCL-XL, and thus senolytic therapy could be a potential effective st
Provides multi-omics evidence linking cellular senescence-related genes to rheumatoid arthritis, supporting br… MEDIUM▼
Rheumatoid arthritis (RA) is a complex autoimmune disease. Recently, cell senescence has been identified as a key factor in its pathogenesis. This study integrated multi-omics summary data and applied Mendelian randomization (MR) and co-localization analysis to systematically evaluate the causal relationships between cell senescence-related genes and RA. We collected summary data on blood methylation quantitative trait loci (mQTL), expression quantitative trait loci, and protein quantitative tra
Demonstrates increased apoptotic priming and BCL-X(L) dependence in aging platelets, which aligns with the sen… MEDIUM▼
Platelets are short-lived anucleate cells essential for primary hemostasis and recognized for their functions in thrombosis, immunity, antimicrobial defense, neurodegeneration, as well as cancer growth and metastasis. Their brief lifespan in circulation is controlled by the removal of sialic acid residues from the platelet surface (desialylation) and also the mitochondrial apoptosis pathway, with high expression of the anti-apoptotic protein BCL-XL being required for platelet survival. This depe
Shows mechanisms of Bcl-X(L) degradation under stress responses, directly relevant to senolytic targeting stra… MEDIUM▼
The human WWOX gene resides on a common fragile site and is frequently deleted or altered during DNA replication. WWOX mutations are associated with various human diseases, including cancer, neurodegeneration, and developmental deficits. However, the regulation of WWOX expression remains largely unclear. We demonstrated that stress responses, including serum deprivation, oxidative stress, and anticancer drug treatment, increase WWOX expression in human SCC-15 cells and wild-type mouse embryonic
Explores targeting BCL-X(L) to overcome resistance, which is conceptually aligned with the proposed senolytic … MEDIUM▼
Venetoclax (VEN)-based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non-receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3-ITD) are common in resistant patients and are linked to activation of mitogen-activated protein kinase (MAPK) signalling and increased expression of anti-apoptotic proteins such as myeloid cel
Demonstrates metformin's ability to reduce senescence induced by inflammation, supporting broader senescence i… MEDIUM▼
Obesity contributes to worse outcomes in breast cancer, particularly in the luminal subtype, where cellular senescence could increase tumor aggressiveness. Parallelly, Estrogen Receptor Beta (ERβ) has emerged as an important mediator in the cellular response to obesity-associated inflammation that metformin could counteract. This study explores metformin's role in targeting senescence to mitigate obesity-induced tumor progression. Using the GSE189757 dataset, differentially expressed genes in ob
Provides evidence for targeting BCL-X(L) for degradation, directly supporting the senolytic mechanism in the h… MEDIUM▼
Cholangiocarcinoma (CCA) remains a highly lethal malignancy with a dismal prognosis, primarily driven by therapeutic resistance. A dominant resistance mechanism involves overexpression of anti-apoptotic BCL-2 proteins (BCL-XL, BCL-2, MCL-1). While direct inhibition of these proteins shows efficacy, its clinical utility is frequently limited by dose-dependent hematotoxicity-as exemplified by ABT263, a BCL-XL/BCL-2 dual inhibitor that induces severe thrombocytopenia. We performed integrated analys
✗ Opposing Evidence 6
Suggests sex-specific effects may complicate therapeutic development
Caloric Restriction Intervention Alters Specific Circulating Biomarkers of the Senescence-Associated Secretome… MEDIUM▼
Lifestyle interventions may address senescence without drug risks
Wholesale senescent cell elimination may have unintended consequences
Safety concern requiring careful dose optimization
The importance of phosphorylation and dephosphorylation in intracellular signaling pathways has long been recognized, although attention has focused mainly on kinases. Recent studies have highlighted the importance of serine/threonine protein phosphatases in many processes including apoptosis. The phosphorylation state of antiapoptotic (Bcl-2, Bcl-X(L)) and proapoptotic (BAD, Bid, Bik) Bcl-2 proteins regulates their cellular activity and, therefore, cell survival and cell death. For example, dephosphorylation of BAD by the protein phosphatases PP1, PP2A and PP2B allows BAD to interact with Bcl-X(L) and initiate cell death. Caspases are also important in cell death and phosphorylation/dephosphorylation of caspases themselves, their targets and their regulators modulates apoptotic pathways. The activity of serine/threonine protein phosphatases needs further study, but it is clear that these enzymes are potential targets for novel therapeutics with applications in many diseases, including cancer, inflammatory diseases and neurodegeneration.
Beclin 1, the mammalian orthologue of yeast Atg6, has a central role in autophagy, a process of programmed cell survival, which is increased during periods of cell stress and extinguished during the cell cycle. It interacts with several cofactors (Atg14L, UVRAG, Bif-1, Rubicon, Ambra1, HMGB1, nPIST, VMP1, SLAM, IP(3)R, PINK and survivin) to regulate the lipid kinase Vps-34 protein and promote formation of Beclin 1-Vps34-Vps15 core complexes, thereby inducing autophagy. In contrast, the BH3 domain of Beclin 1 is bound to, and inhibited by Bcl-2 or Bcl-XL. This interaction can be disrupted by phosphorylation of Bcl-2 and Beclin 1, or ubiquitination of Beclin 1. Interestingly, caspase-mediated cleavage of Beclin 1 promotes crosstalk between apoptosis and autophagy. Beclin 1 dysfunction has been implicated in many disorders, including cancer and neurodegeneration. Here, we summarize new findings regarding the organization and function of the Beclin 1 network in cellular homeostasis, focusing on the cross-regulation between apoptosis and autophagy.
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Novel Therapeutic Hypotheses for Neuroinflammation Resolution
1. Microglial Efferocytosis Enhancement via GPR32 Superagonists
Description: Synthetic super-agonists of GPR32 (RvD1 receptor) could restore microglial phagocytic capacity for clearing protein aggregates and apoptotic neurons. Enhanced efferocytosis would break the cycle of failed clearance that perpetuates chronic neuroinflammation in neurodegeneration.Target: GPR32 (CMKLR1) receptor and downstream PI3K/Akt signaling
Supporting Evidence: GPR32 activation promotes microglial M2 polarization (PMID: 27432871). Def
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and alternative explanations.
1. Microglial Efferocytosis Enhancement via GPR32 Superagonists
Specific Weaknesses:
- GPR32 expression varies dramatically across brain regions and disease states - superagonists may cause region-specific toxicity
- The cited RvD1/Aβ clearance study (PMID: 28814792) used systemic administration with unclear CNS penetration
- "Superagonists" implies supraphysiological activation that could trigger receptor desensitization or adverse downstream effects
- No evidence that GPR32
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
Practical Feasibility Assessment: Neuroinflammation Resolution Hypotheses
1. Microglial Efferocytosis Enhancement via GPR32 Superagonists
Druggability Assessment: MODERATE
- Target: GPR32 (CMKLR1) is a Class A GPCR - well-established druggable class
- Chemical Matter: Limited but emerging
- Existing compounds: Resolvin D1 (natural ligand, poor stability)
- Synthetic analogs: AT-RvD1 (aspirin-triggered RvD1), more stable
- Tool compounds: CMKLR1 selective agonists from Amgen (unpublished)
Competitive Landscape:
- Direct competitors: None in clin
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| ⚖ | Recalibrated | $0.786 | ▲ 36.5% | market_dynamics | 2026-04-23 04:12 |
| ⚖ | Recalibrated | $0.576 | ▼ 2.7% | market_dynamics | 2026-04-13 03:33 |
| 📄 | New Evidence | $0.592 | ▲ 0.6% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.588 | ▲ 8.8% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.541 | ▼ 1.9% | 2026-04-12 05:13 | |
| ⚖ | Recalibrated | $0.551 | ▼ 0.5% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.554 | ▲ 0.6% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.551 | ▲ 1.7% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.542 | ▲ 2.2% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.530 | ▼ 0.6% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.533 | ▼ 0.8% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.538 | ▲ 2.1% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.527 | ▼ 21.7% | 2026-04-03 23:46 | |
| 📄 | New Evidence | $0.672 | ▲ 1.7% | evidence_batch_update | 2026-04-03 01:06 |
| ⚖ | Recalibrated | $0.661 | ▲ 6.3% | market_dynamics | 2026-04-03 01:06 |
Clinical Trials (10) Relevance: 60%
Active
Completed
Total Enrolled
Highest Phase
📚 Cited Papers (48)
📙 Related Wiki Pages (15)
📓 Linked Notebooks (1)
📊 Resource Economics & ROI
Cost Ratios
Score Impact
How Economics Pricing Works
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Efficiency Price Signals
| Date | Signal Price | Score |
|---|---|---|
| 2026-04-16T20:00 | $0.560 | 0.537 |
Wiki Pages
KG Entities (47)
Dependency Graph (1 upstream, 3 downstream)
Linked Experiments (9)
Related Hypotheses
Estimated Development
🧪 Falsifiable Predictions (21)
Knowledge Subgraph (131 edges)
associated with (2)
co associated with (20)
co discussed (81)
▸ Show 76 more
encodes (6)
▸ Show 1 more
implicated in (7)
▸ Show 2 more
mediates (2)
participates in (7)
promotes (1)
resolves (1)
Mechanism Pathway for BCL2L1
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
BCL2L1["BCL2L1"] -->|encodes| BCL_xL["BCL-xL"]
BCL2L1_1["BCL2L1"] -->|associated with| neurodegeneration["neurodegeneration"]
BCL2L1_2["BCL2L1"] -->|participates in| Microglial_activation___T["Microglial activation / TREM2 signaling"]
ALOX15["ALOX15"] -->|co discussed| BCL2L1_3["BCL2L1"]
BCL2L1_4["BCL2L1"] -->|co discussed| TFRC["TFRC"]
BCL2L1_5["BCL2L1"] -->|co discussed| GPR37["GPR37"]
BCL2L1_6["BCL2L1"] -->|co discussed| CMKLR1["CMKLR1"]
BCL2L1_7["BCL2L1"] -->|co discussed| ALOX12["ALOX12"]
BCL2L1_8["BCL2L1"] -->|co discussed| ALOX5["ALOX5"]
CMKLR1_9["CMKLR1"] -->|co discussed| BCL2L1_10["BCL2L1"]
ALOX12_11["ALOX12"] -->|co discussed| BCL2L1_12["BCL2L1"]
ALOX5_13["ALOX5"] -->|co discussed| BCL2L1_14["BCL2L1"]
GPR37_15["GPR37"] -->|co discussed| BCL2L1_16["BCL2L1"]
TFRC_17["TFRC"] -->|co discussed| BCL2L1_18["BCL2L1"]
BCL2L1_19["BCL2L1"] -->|co discussed| ALOX15_20["ALOX15"]
style BCL2L1 fill:#ce93d8,stroke:#333,color:#000
style BCL_xL fill:#4fc3f7,stroke:#333,color:#000
style BCL2L1_1 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style BCL2L1_2 fill:#ce93d8,stroke:#333,color:#000
style Microglial_activation___T fill:#81c784,stroke:#333,color:#000
style ALOX15 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_3 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_4 fill:#ce93d8,stroke:#333,color:#000
style TFRC fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_5 fill:#ce93d8,stroke:#333,color:#000
style GPR37 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_6 fill:#ce93d8,stroke:#333,color:#000
style CMKLR1 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_7 fill:#ce93d8,stroke:#333,color:#000
style ALOX12 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_8 fill:#ce93d8,stroke:#333,color:#000
style ALOX5 fill:#ce93d8,stroke:#333,color:#000
style CMKLR1_9 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_10 fill:#ce93d8,stroke:#333,color:#000
style ALOX12_11 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_12 fill:#ce93d8,stroke:#333,color:#000
style ALOX5_13 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_14 fill:#ce93d8,stroke:#333,color:#000
style GPR37_15 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_16 fill:#ce93d8,stroke:#333,color:#000
style TFRC_17 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_18 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1_19 fill:#ce93d8,stroke:#333,color:#000
style ALOX15_20 fill:#ce93d8,stroke:#333,color:#000
3D Protein Structure
🧬 BCL2L1 — PDB 1MAZ Click to expand 3D viewer
Source Analysis
Neuroinflammation resolution mechanisms and pro-resolving mediators
neurodegeneration | 2026-04-01 | completed
Community Feedback
No comments yet. Be the first to comment!